Citigroup Maintains Buy on Apogee Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Citigroup analyst Geoff Meacham maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $95 to $125.